Sun Pharma Advanced Research 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Anilkumar Raghavan

최고 경영자

₹69.6m

총 보상

CEO 급여 비율	n/a
CEO 임기	10.6yrs
CEO 소유권	n/a
경영진 평균 재임 기간	1.2yrs
이사회 평균 재임 기간	7.5yrs

최근 관리 업데이트

Recent updates

CEO

Anilkumar Raghavan (56 yo)

10.6yrs

테뉴어

₹69,608,000

보상

Mr. Anilkumar Raghavan has been the Chief Executive Officer of Sun Pharma Advanced Research Company Limited since April 24, 2014. Mr. Raghavan is a senior pharmaceutical services executive with significant...

리더십 팀

이름	위치	테뉴어	보상	소유권
Anilkumar Raghavan	Chief Executive Officer	10.6yrs	₹69.61m	데이터 없음
Anup Rathi	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Nitin Dharmadhikari	Chief Operating Officer	less than a year	데이터 없음	데이터 없음
Jaydeep Issrani	Senior General Manager of Business Development	no data	데이터 없음	데이터 없음
Kajal Damania	Company Secretary & Compliance Officer	1.2yrs	데이터 없음	데이터 없음
Shanta Gupta	Chief Human Resource Officer	4.8yrs	데이터 없음	데이터 없음
Siu-Long Yao	Head Clinical Development	less than a year	데이터 없음	데이터 없음
Nitin Damle	Chief Innovation Officer	no data	데이터 없음	데이터 없음
Yashoraj Zala	Head of Drug Delivery Systems	no data	데이터 없음	데이터 없음
Vikram Ramanathan	Head of Preclinical Development	5.6yrs	데이터 없음	데이터 없음
Venkata Palle	Global Head of Drug Discovery & Preclinical Development	1.7yrs	데이터 없음	데이터 없음
Shravanti Bhowmik	VP & Head Operations Management	less than a year	데이터 없음	데이터 없음

1.2yrs

평균 재임 기간

경험이 풍부한 관리: 532872 의 관리팀은 경험 (평균 재직 기간 1.2 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Dilip Shanghvi	Chairman	18.7yrs	₹390.00k	19.06% ₹ 12.9b
Robert Jay Spiegel	Independent Director	4.4yrs	₹630.00k	데이터 없음
Bhavna Doshi	Independent Director	10.1yrs	₹660.00k	데이터 없음
Thennati Rajamannar	Non-Executive Non-Independent Director	17.4yrs	₹300.00k	0.011% ₹ 7.5m
Vidhi Shanghvi	Additional Non-Executive Non-Independent Director	less than a year	데이터 없음	데이터 없음
Ferzaan Engineer	Independent Director	7.5yrs	₹630.00k	데이터 없음
Mark Simon	Member of Advisory Board	3.9yrs	₹570.00k	데이터 없음

7.5yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: 532872 의 이사회는 경험(평균 재직 기간 7.5 년)으로 간주됩니다.

Sun Pharma Advanced Research 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Sun Pharma Advanced Research Company Limited Appoints Vidhi Dilip Shanghvi as A Non- Executive, Non-Independent Director

Sun Pharma Advanced Research Company Limited Announces Re-Designation of Nitin Dharmadhikari as Chief Operating Officer

Sun Pharma Advanced Research Company Limited, Annual General Meeting, Aug 12, 2024

Sun Pharma Advanced Research Company Limited, Annual General Meeting, Aug 12, 2024

Sun Pharma Advanced Research Company Limited Announces Chief Financial Officer Changes

Insufficient new directors

Recent updates

New major risk - Negative shareholders equity

Second quarter 2025 earnings released: ₹3.31 loss per share (vs ₹2.66 loss in 2Q 2024)

New major risk - Revenue and earnings growth

Sun Pharma Advanced Research Company Limited to Report Q2, 2025 Results on Nov 04, 2024

Sun Pharma Advanced Research Company Limited Appoints Vidhi Dilip Shanghvi as A Non- Executive, Non-Independent Director

Sun Pharma Advanced Research Company Limited to Report Q1, 2025 Results on Aug 05, 2024

Sun Pharma Advanced Research Company Limited Announces Re-Designation of Nitin Dharmadhikari as Chief Operating Officer

Full year 2024 earnings released: ₹11.93 loss per share (vs ₹7.82 loss in FY 2023)

Sun Pharma Advanced Research Company Limited, Annual General Meeting, Aug 12, 2024

Sun Pharma Advanced Research Company Limited, Annual General Meeting, Aug 12, 2024

Sun Pharma Advanced Research Company Limited Announces Chief Financial Officer Changes

Sun Pharma Advanced Research Company Limited to Report Q4, 2024 Results on May 24, 2024

Third quarter 2024 earnings released: ₹3.07 loss per share (vs ₹0.37 profit in 3Q 2023)

Sun Pharma Advanced Research Company Limited to Report Q3, 2024 Results on Feb 05, 2024

Insufficient new directors

Second quarter 2024 earnings released: ₹2.66 loss per share (vs ₹2.52 loss in 2Q 2023)

Sun Pharma Advanced Research Company Limited Announces Retirement of Chitturi Trinadha Rao as Senior Vice President, Drug Discovery

Sun Pharma Advanced Research Company Limited to Report Q2, 2024 Results on Nov 06, 2023

Sun Pharma Advanced Research Company Limited Appoints Kajal Damania as Company Secretary

Sun Pharma Advanced Research Company Limited Announces the Resignation of Mr. Dinesh Lahoti as Company Secretary and Compliance Officer

Sun Pharma Advanced Research Company Limited to Report Q1, 2024 Results on Aug 07, 2023

Full year 2023 earnings released: ₹7.82 loss per share (vs ₹7.73 loss in FY 2022)

Sun Pharma Advanced Research Company Limited Announces That FDA Issues Complete Response Letter for Pdp-716 Nda Due to Inspection Findings At Third-Party Api Manufacturing Facility

Sun Pharma Advanced Research Company Limited, Annual General Meeting, Aug 07, 2023

Full year 2023 earnings released: ₹7.82 loss per share (vs ₹7.73 loss in FY 2022)

Sun Pharma Advanced Research Company Limited to Report Q4, 2023 Results on May 22, 2023

Third quarter 2023 earnings released: EPS: ₹0.37 (vs ₹0.60 loss in 3Q 2022)

Sun Pharma Advanced Research Company Limited to Report Q3, 2023 Results on Feb 13, 2023

Sun Pharmaceutical Industries Limited and Sun Pharma Advanced Research Company Limited Announces U.S. FDA Approval of SEZABY (Phenobarbital Sodium Powder for Injection) for the Treatment of Neonatal Seizures

Second quarter 2023 earnings released: ₹2.52 loss per share (vs ₹2.09 loss in 2Q 2022)

Sun Pharma Advanced Research Company Limited to Report Q2, 2023 Results on Nov 07, 2022

Sun Pharma Advanced Research Company Limited, Annual General Meeting, Sep 22, 2022

First quarter 2023 earnings released: ₹3.03 loss per share (vs ₹2.34 loss in 1Q 2022)

Sun Pharma Advanced Research Company Limited to Report Q1, 2023 Results on Aug 08, 2022

Full year 2022 earnings released: ₹7.73 loss per share (vs ₹5.77 loss in FY 2021)

Sun Pharma Advanced Research Company Limited to Report Q4, 2022 Results on May 17, 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released: ₹2.09 loss per share (vs ₹3.19 loss in 2Q 2021)

Director Bhavna Doshi has joined 6th company board

Director Bhavna Doshi has joined 6th company board

Director Bhavna Doshi has joined 6th company board

Director Bhavna Doshi has joined 6th company board

Director Bhavna Doshi has joined 6th company board

Director Bhavna Doshi has joined 6th company board

Director Bhavna Doshi has joined 6th company board

Director Bhavna Doshi has joined 6th company board

First quarter 2022 earnings released: ₹2.34 loss per share (vs ₹2.16 profit in 1Q 2021)

Full year 2021 earnings released: ₹5.77 loss per share (vs ₹11.92 loss in FY 2020)

Sun Pharma Advanced Research Company Ltd. Reports Positive Top-Line Results from Its Phase 3 Trial for Its Investigational Drug

Sun Pharma Advanced Research Company Limited announced that it expects to receive INR 3.002424034 billion in funding from a group of investors

Sun Pharma Advanced Research Company Limited Announces the U.S. Food and Drug Administration Deny Appeal of the Complete Response Letter

New 90-day low: ₹173

Third quarter 2021 earnings released: ₹2.58 loss per share (vs ₹2.12 loss in 3Q 2020)

Sun Pharma Advanced Research Company Limited to Report Q3, 2021 Results on Feb 08, 2021

New 90-day high: ₹194

New 90-day high: ₹185

Second quarter 2021 earnings released: ₹3.19 loss per share

Sun Pharma Advanced Research Company Limited to Report Q2, 2021 Results on Nov 09, 2020

New 90-day low: ₹165

Sun Pharma Advanced Research Company Limited Announces the Grant of an Exclusive License to Tripoint Therapeutics Llc, USA (Tripoint) to Commercialize Elepsia Xr 1000 Mg and Elepsia Xr 1500 Mg Tablets

New 90-day high - ₹190

First quarter earnings released

Sun Pharma Advanced Research Company Limited to Report Q1, 2021 Results on Aug 04, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

이사회 구성원